312 related articles for article (PubMed ID: 20866166)
1. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management.
Johnson FR; Hauber B; Özdemir S; Siegel CA; Hass S; Sands BE
J Manag Care Pharm; 2010 Oct; 16(8):616-28. PubMed ID: 20866166
[TBL] [Abstract][Full Text] [Related]
2. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy.
Johnson FR; Ozdemir S; Mansfield C; Hass S; Miller DW; Siegel CA; Sands BE
Gastroenterology; 2007 Sep; 133(3):769-79. PubMed ID: 17628557
[TBL] [Abstract][Full Text] [Related]
3. Are adult patients more tolerant of treatment risks than parents of juvenile patients?
Johnson FR; Ozdemir S; Mansfield C; Hass S; Siegel CA; Sands BE
Risk Anal; 2009 Jan; 29(1):121-36. PubMed ID: 18826414
[TBL] [Abstract][Full Text] [Related]
4. Which Factors Are Considered by Patients When Considering Total Joint Arthroplasty? A Discrete-choice Experiment.
Salimy MS; Humphrey TJ; Katakam A; Melnic CM; Heng M; Bedair HS
Clin Orthop Relat Res; 2023 Mar; 481(3):427-437. PubMed ID: 36111881
[TBL] [Abstract][Full Text] [Related]
5. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab for induction of remission in Crohn's disease.
Macdonald JK; McDonald JW
Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
[TBL] [Abstract][Full Text] [Related]
7. Understanding the role of the primary care physician in the management of patients with Crohn's perianal fistulas.
Salinas GD; Belcher E; Stacy S; Nazarey PP; Cazzetta SE
Postgrad Med; 2024 Jan; 136(1):67-77. PubMed ID: 38445664
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Gastroenterologists' Perceptions Regarding Ulcerative Colitis and Its Management: Results from a Large-Scale Survey.
Lasch K; Liu S; Ursos L; Mody R; King-Concialdi K; DiBonaventura M; Leberman J; Dubinsky M
Adv Ther; 2016 Oct; 33(10):1715-1727. PubMed ID: 27509887
[TBL] [Abstract][Full Text] [Related]
10. Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment.
Hazlewood GS; Pokharel G; Deardon R; Marshall DA; Bombardier C; Tomlinson G; Ma C; Seow CH; Panaccione R; Kaplan GG
PLoS One; 2020; 15(1):e0227635. PubMed ID: 31945089
[TBL] [Abstract][Full Text] [Related]
11. Patient preferences between surgical and medical treatment in Crohn's disease.
Byrne CM; Solomon MJ; Young JM; Selby W; Harrison JD
Dis Colon Rectum; 2007 May; 50(5):586-97. PubMed ID: 17380368
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab for induction of remission in Crohn's disease.
MacDonald JK; McDonald JW
Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
[TBL] [Abstract][Full Text] [Related]
13. Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists.
Baji P; Gulácsi L; Lovász BD; Golovics PA; Brodszky V; Péntek M; Rencz F; Lakatos PL
Scand J Gastroenterol; 2016 Jan; 51(1):22-7. PubMed ID: 26059967
[TBL] [Abstract][Full Text] [Related]
14. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
MacDonald JK; Nguyen TM; Khanna R; Timmer A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
[TBL] [Abstract][Full Text] [Related]
15. Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment.
Gonzalez JM; Johnson FR; McAteer H; Posner J; Mughal F
Br J Dermatol; 2017 Mar; 176(3):777-785. PubMed ID: 27292093
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
18. Patients and gastroenterologists' perceptions of treatments for inflammatory bowel diseases: do their perspectives match?
Vaucher C; Maillard MH; Froehlich F; Burnand B; Michetti P; Pittet V
Scand J Gastroenterol; 2016 Sep; 51(9):1056-61. PubMed ID: 26891800
[TBL] [Abstract][Full Text] [Related]
19. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.
Sinopoulou V; Gordon M; Akobeng AK; Gasparetto M; Sammaan M; Vasiliou J; Dovey TM
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013531. PubMed ID: 34844288
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab for induction of remission in Crohn's disease.
Nelson SM; Nguyen TM; McDonald JW; MacDonald JK
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006097. PubMed ID: 30068022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
